Stayble provides update on the ongoing Phase 2b study due to the covid-19 pandemic
Stayble Therapeutics announced today that recruiting patients for the company's ongoing Phase 2b study with the drug candidate STA363 is slower than expected due to the covid-19 pandemic and the strict pandemic rules with several lock-downs in all study countries. Under current conditions, the company is expected to be able to report study results during the second half of 2022, which is later than previously communicated.“We have been pleased to note that patients continue to be recruited in our study and there is great enthusiasm among the investigators at the participating clinics. At